THE COMPANY

180 Therapeutics, a clinical-stage company, was founded by Professor Sir Marc Feldmann, Professor Jagdeep Nanchahal, and Dr Glenn Larsen in 2013.

The discovery of TNF as a mediator of numerous immune-driven diseases originated from analysis of human disease tissue from patients with rheumatoid arthritis, which identified the key mediators of disease.

180 Therapeutics is applying this same approach to the analysis of human disease tissue from patients with active fibrosis or scarring, which again has led to the development of new therapeutic agents and approaches which 180 Therapeutics is developing.

180 Therapeutics’ first major project, is solving an unmet need, treating early -stage fibrosis of the hand, Dupuytren’s contraction. This is being carried out by a local injection of Humira, an anti-TNF antibody.

Frozen shoulder, a common affliction affecting up to 2% of the global population, is due to inflammation and is very painful. Detailed plans have been made for a trial involving the local injection of Humira to frozen shoulders. As this condition is painful, cannabidiol will be also used, propelling 180 Therapeutics to the heart of the second-generation medical marijuana field.

THE SCIENCE

180 therapeutics has developed a detailed molecular and cellular characterization of human disease and non-diseased tissue to identify the critical biochemical mediators that are causative in disease. The biochemical analysis of human disease tissue has allowed the unravelling of the molecular mechanisms that initiate and maintain the diseased fibrotic process. These investigations have been successful in leading to the identification of novel pathways capable of modulating human fibrotic disease. This work resulted in the company identifying new disease-modulating targets to treat fibrosis and that anti-TNF therapy can be effective to prevent progression of the disease.

THE ADVANTAGE

A Phase B clinical trial is running and is recruiting well ahead of plans. Recruitment will be complete by March 2019, and final results will be known by the end of 2020. Based on the lack of suitable alternatives, attempts will then be made to seek registration without further trials. 180 Therapeutics may soon have an opportunity to sell its own drugs, and could acquire its own version of fully-tested Humira from Momenta. This would enable to product injected to be owned by the company, which would greatly augment the potential profits, as would the production of pre-loaded syringes.

In the fibrosis field, Professor Nanchahal has made exciting progress, identifying a new target for treatment on the surface of cells, known as the myofibroblast. This could grant the company access to treat liver fibrosis and its precursor fatty liver disease.

TARGET INDICATIONS

The global treatment market for hand fibrosis is expected to reach $5.5 Billion USD in 2023, rising at a CAGR of 4.4% from 2018.

The market for treating liver fibrosis was worth $12.6B USD in 2018, and is expected to rise to $19.54B USD in 2022 at a CAGR of 11.7%.

25% of the 1.3 million hip fracture patients develop post operative delirium. This accounts for 1.4% of the total health burden in the West.

The condition affects 9% of the population aged 25 to 64, and is more common in diabetics. The only current treatment for the early stage is a local steroid injection.